Session Type
Meeting
Search Results for Renal Cell Carcinoma
Abstract Number: 131
Hospital Medicine 2020, Virtual Competition
Background: Acute kidney injury (AKI) is a common complication of renal cell carcinoma or its treatment. It is unclear whether AKI, compared to inpatients with similar clinical and hospital-level characteristics without AKI, is associated with worse clinical outcomes and higher costs. To address this void, our study aimed to evaluate how an AKI diagnosis affects […]
Abstract Number: 131
Hospital Medicine 2020, Virtual Competition
Background: There are several scoring models used for risk stratification of patients presenting with chest pain. The HEART score is a tool recently developed in a European cohort of patients. It combines 5 elements: history, EKG, age, risk factors, and troponin. We aimed to compare its predictive value with that of TIMI and GRACE scores […]
Abstract Number: 694
Hospital Medicine 2020, Virtual Competition
Case Presentation: Introduction: Renal cell carcinoma (RCC) is classically associated with the triad of abdominal pain, hematuria, and a palpable mass, but its variability in clinical presentation has earned it the label of “internist’s tumor” (1,2). Liver dysfunction has been observed as a result of metastatic disease and a non-metastatic paraneoplastic syndrome called Stauffer’s syndrome […]
Abstract Number: 694
Hospital Medicine 2020, Virtual Competition
Case Presentation: An 86-year-old male with hypertension, diabetes, and pulmonary tuberculosis on therapy presented to the ED with fever and a rash. He developed an erythematous rash over his body two months prior to admission. At that time, he had completed the initial phase of RIPE therapy and was only on Isoniazid and Rifampin. Both […]
Abstract Number: 1164
Hospital Medicine 2020, Virtual Competition
Case Presentation: A 52 year-old woman with a two-month history of metastatic clear cell renal cell carcinoma presented to the emergency department from oncology clinic with one week of malaise and nausea. She also reported subacute onset of dizziness and fever. She received her second cycle of palliative immunotherapy with ipilimumab/nivolumab 14 days prior to […]